Nasdaq ardx.

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Feb 15, 2023 · In the latest trading session, Ardelyx (ARDX) closed at $3.02, marking a -1.63% move from the previous day. This change lagged the S&P 500's 0.28% gain on the day. At the same time, the Dow added ... Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Ardelyx has an average ...Ardelyx (NASDAQ: ARDX) stock is climbing today after the U.S. Food and Drug Administration ( FDA) approved the firm’s treatment for excessive phosphate levels in kidney disease patients. Shares ...

WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...730% upside stock according to Citigroup Ardelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the …

Apr 24, 2023 · Ardelyx (NASDAQ:ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ... Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ...

Find real-time ARDX - Ardelyx Inc stock quotes, company profile, news and forecasts from CNN Business. ... Ardelyx Inc (NASDAQ:ARDX) Real-Time Quotes. 4.55. BATS BZX Real-Time Price. As of 10:35am ETARDX Ardelyx Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... This section uses the official NASDAQ-supplied short interest and provides some value-added metrics, calculated daily. Short Interest is updated twice monthly on set schedule, but float and shares outstanding are on a different update schedule, so we ...Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation. Analyst Price Forecast Suggests 77.74% Upside. As of August ...Real time Ardelyx (ARDX) stock price quote, stock graph, news & analysis.

WALTHAM, Mass., June 5, 2023 – Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that ...

Oct 31, 2023 · Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago. These ...

Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor for adult patients with CKD on dialysis with hyperphosphatemia. The company will host a conference call on December 29, 2022, at 8:00 AM ET. To participate in the conference call, please call (866) 374-5140 (toll-free) or (404) 400-0571 (toll) and …Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Ardelyx has an average ...Ardelyx, Inc. (NASDAQ:ARDX) has gained about 353% over the past 12 months. As of the end of the first quarter of 2023, 20 hedge funds tracked by Insider Monkey were long Ardelyx, Inc. (NASDAQ:ARDX ...Oct 31, 2023 · Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago. These ... Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

Ardelyx Inc (NASDAQ:ARDX)’s Major holders. Ardelyx Inc insiders own 1.74% of total outstanding shares while institutional holders control 56.10%, with the float percentage being 57.09%. State Street Corporation is the largest shareholder of the company, while 176 institutions own stock in it. As of Jun 29, 2023, the company held …The bid-ask spread can indicate a stock's liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher ...Find the latest historical data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. Ardelyx Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ARDX updated stock price target summary.Nov 17, 2023 · ARDELYX INC ( ARDX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...

Ardelyx, Inc. ( NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...

The chain sheet shows the price, volume and open interest for each option strike price and expiration month. Nasdaq provides call and put options information of stocks. Financial analysts and ...Market Activity. Funds + ETFs. After-Hours Quotes. News + Insights. P/E & PEG Ratios. . Here you can find up-to-the-minute news and analysis of the company that you are researching for potential ... WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ...WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ...ARDX Stock 12 Months Forecast. $9.92. (177.48% Upside) Based on 7 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $9.92 with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 177.48% change from the last price of $3.58. EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.10. 3 Months Ago. -$0.11. Ardelyx Inc. analyst estimates, including ARDX earnings per share estimates and analyst recommendations.WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult ...

Ardelyx, Inc. Reports Employment Inducement Grants. WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on …

Aug 26, 2023 · Ardelyx (NASDAQ:ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ... ARDX ARDX AFTER HOURS QUOTE ARDX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...WALTHAM, Mass., Dec. 29, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research of the U ...Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript October 31, 2023 Ardelyx, Inc. beats earnings expectations. Reported EPS is $0.02909, expectations were $-0.11. Operator: Good day and ...14 thg 9, 2023 ... Fintel reports that on September 13, 2023, Wedbush reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Outperform recommendation.Find real-time ARDX - Ardelyx Inc stock quotes, company profile, news and forecasts from CNN Business. ... Ardelyx Inc (NASDAQ:ARDX) Real-Time Quotes. 4.55. BATS BZX Real-Time Price. As of 10:35am ETArdelyx Inc (NASDAQ:ARDX) 4.34 Delayed Data As of Nov 17 +0.305 / +7.57% Today’s Change 1.56 Today ||| 52-Week Range 5.13 +52.11% Year-to-Date Quote Profile News …The chain sheet shows the price, volume and open interest for each option strike price and expiration month. Nasdaq provides call and put options information of stocks. Financial analysts and ...NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...For example, the Ardelyx, Inc. (NASDAQ:ARDX) share price had more than doubled in just one year - up 226%. And in the last month, the share price has gained …Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ...

Dec 3, 2023 · Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report released on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price objective would suggest a potential upside of 89.08% from the company’s previous close. Several other ... Webull offers ARDX Ent Holdg (ARDX) historical stock prices, in-depth market analysis, NASDAQ: ARDX real-time stock quote data, in-depth charts, free ARDX ...25 thg 9, 2023 ... Ardelyx's (NASDAQ:ARDX) Kidney Disease Therapy Bags Approval in Japan ... Ardelyx's lead candidate, tenapanor, has bagged approval in Japan for ...Instagram:https://instagram. td ameritrade paper trading optionsonl'iai stockfintech charlotte Nasdaq 14,305.03 +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Advertisement Ardelyx, Inc. (ARDX) … insiders selling stockhealthcare worker mortgage loans Sep 28, 2023 · WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ... kitseyecare Nov 24, 2023 · Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult ... Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Real time Ardelyx (ARDX) stock price quote, stock graph, news & analysis.